Patients who stayed on GLP-1s continuously saw an 18% reduction in cardiovascular risk compared to patients taking sulfonylureas. But stopping for as little as six months erased much of that protection, raising risk by 4% compared to continued use. After two years off treatment, cardiovascular risk rose by 22% compared with continuous use, according to a report in BMJ Medicine.
News
Diabetes patients who stop GLP-1 drugs increase their heart risks
March 20, 2026Patients who stayed on GLP-1s continuously saw an 18% reduction in cardiovascular risk compared to patients taking sulfonylureas. But stopping for as little as six months erased much of that protection, raising risk by 4% compared to continued use. After two years off treatment, cardiovascular risk rose by 22% compared with continuous use, according to a report in BMJ Medicine.